Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 


Proteon Therapeutics, Inc.

Notes to Financial Statements (Continued)

11. Stock-based Compensation (Continued)

        Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company's statements of operations as follows (in thousands):

 
  Years Ended
December 31,
  Six Months
Ended
June 30,
 
 
  2012   2013   2013   2014  
 
   
   
  (unaudited)
 

Research and development

  $ 46   $ 106   $ 84   $ 21  

General and administrative

    64     49     21     28  
                   

Total

  $ 110   $ 155   $ 105   $ 49  
                   
                   

        A following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands):

 
  Shares   Weighted-
Average
Exercise
Price
  Weighted-
Average
Remaining
Contractual
Term (years)
  Aggregate
Intrinsic
Value
 

Outstanding at December 31, 2012

    613,590   $ 2.06     6.2   $ 12,370  

Granted

    3,150   $ 22.22              

Exercised

    (9,298 ) $ 2.06              

Cancelled or forfeited

    (425 ) $ 2.54              
                         

Outstanding at December 31, 2013

    607,017   $ 2.22     5.2   $ 1,627  
                         

Granted (unaudited)

    527,718   $ 4.92              

Exercised (unaudited)

    (473 ) $ 1.27              

Cancelled or forfeited (unaudited)

      $              
                         

Outstanding at June 30, 2014 (unaudited)

    1,134,262   $ 3.49     7.2   $ 1,722  
                         

Exercisable at December 31, 2013

    509,609   $ 2.22     4.7   $ 1,307  
                         

Vested or expected to vest at December 31, 2013(1)

    583,625   $ 2.22     5.1   $ 1,561  
                         

Exercisable at June 30, 2014 (unaudited)

    536,583   $ 2.22     4.4   $ 1,483  
                         

Vested or expected to vest at June 30, 2014 (unaudited)(1)

    1,062,276   $ 3.33     7.0   $ 1,668  
                         
                         

(1)
This represents the number of vested options at December 31, 2013 and June 30, 2014 (unaudited), plus the number of unvested options expected to vest at December 31, 2013 and June 30, 2014 (unaudited), based on the unvested options outstanding at December 31, 2013 and June 30, 2014 (unaudited).

        During the year ended December 31, 2013 and the six months ended June 30, 2013 (unaudited), the Company granted stock options to purchase an aggregate of 3,150 shares of its Common Stock with a weighted-average grant date fair value of $16.50. During the six months ended June 30, 2014 (unaudited) the Company granted stock options to purchase an aggregate of 527,718 shares of its Common Stock with a weighted-average grant date fair value of $3.38.

F-28